204 related articles for article (PubMed ID: 37615015)
1. Natural Killer Cell Activation by Ubiquitin-specific Protease 6 Mediates Tumor Suppression in Ewing Sarcoma.
Jain K; Henrich IC; Quick L; Young R; Mondal S; Oliveira AM; Blobel GA; Chou MM
Cancer Res Commun; 2023 Aug; 3(8):1615-1627. PubMed ID: 37615015
[TBL] [Abstract][Full Text] [Related]
2. Ubiquitin-Specific Protease 6 Functions as a Tumor Suppressor in Ewing Sarcoma through Immune Activation.
Henrich IC; Jain K; Young R; Quick L; Lindsay JM; Park DH; Oliveira AM; Blobel GA; Chou MM
Cancer Res; 2021 Apr; 81(8):2171-2183. PubMed ID: 33558334
[TBL] [Abstract][Full Text] [Related]
3. USP6 Confers Sensitivity to IFN-Mediated Apoptosis through Modulation of TRAIL Signaling in Ewing Sarcoma.
Henrich IC; Young R; Quick L; Oliveira AM; Chou MM
Mol Cancer Res; 2018 Dec; 16(12):1834-1843. PubMed ID: 30131449
[TBL] [Abstract][Full Text] [Related]
4. Prospects and Advances in Adoptive Natural Killer Cell Therapy for Unmet Therapeutic Needs in Pediatric Bone Sarcomas.
Bareke H; Ibáñez-Navarro A; Guerra-García P; González Pérez C; Rubio-Aparicio P; Plaza López de Sabando D; Sastre-Urgelles A; Ortiz-Cruz EJ; Pérez-Martínez A
Int J Mol Sci; 2023 May; 24(9):. PubMed ID: 37176035
[TBL] [Abstract][Full Text] [Related]
5. Ubiquitin-specific protease TRE17/USP6 promotes tumor cell invasion through the regulation of glycoprotein CD147 intracellular trafficking.
Ogura Y; Ohbayashi N; Kanaho Y; Kawaguchi A; Funakoshi Y
J Biol Chem; 2022 Sep; 298(9):102335. PubMed ID: 35926707
[TBL] [Abstract][Full Text] [Related]
6. Ewing Sarcoma Single-cell Transcriptome Analysis Reveals Functionally Impaired Antigen-presenting Cells.
Visser LL; Bleijs M; Margaritis T; van de Wetering M; Holstege FCP; Clevers H
Cancer Res Commun; 2023 Oct; 3(10):2158-2169. PubMed ID: 37823774
[TBL] [Abstract][Full Text] [Related]
7. Zoledronic acid negatively affects the expansion of in vitro activated human NK cells and their cytolytic interactions with Ewing sarcoma cells.
Mueller SK; Altvater B; Chen C; Kailayangiri S; Ahlmann M; Dirksen U; Juergens H; Rossig C
Oncol Rep; 2013 Jun; 29(6):2348-54. PubMed ID: 23525469
[TBL] [Abstract][Full Text] [Related]
8. Enhancing Natural Killer Cell Targeting of Pediatric Sarcoma.
Omer N; Nicholls W; Ruegg B; Souza-Fonseca-Guimaraes F; Rossi GR
Front Immunol; 2021; 12():791206. PubMed ID: 34804076
[TBL] [Abstract][Full Text] [Related]
9. Pro-inflammatory chemokine-chemokine receptor interactions within the Ewing sarcoma microenvironment determine CD8(+) T-lymphocyte infiltration and affect tumour progression.
Berghuis D; Santos SJ; Baelde HJ; Taminiau AH; Egeler RM; Schilham MW; Hogendoorn PC; Lankester AC
J Pathol; 2011 Feb; 223(3):347-57. PubMed ID: 21171080
[TBL] [Abstract][Full Text] [Related]
10. Insulin-like growth factor-1 receptor (IGF-1R) inhibition promotes expansion of human NK cells which maintain their potent antitumor activity against Ewing sarcoma cells.
Jamitzky S; Krueger AC; Janneschuetz S; Piepke S; Kailayangiri S; Spurny C; Rossig C; Altvater B
Pediatr Blood Cancer; 2015 Nov; 62(11):1979-85. PubMed ID: 26131572
[TBL] [Abstract][Full Text] [Related]
11. Preclinical Testing of an Oncolytic Parvovirus in Ewing Sarcoma: Protoparvovirus H-1 Induces Apoptosis and Lytic Infection In Vitro but Fails to Improve Survival In Vivo.
Lacroix J; Kis Z; Josupeit R; Schlund F; Stroh-Dege A; Frank-Stöhr M; Leuchs B; Schlehofer JR; Rommelaere J; Dinsart C
Viruses; 2018 Jun; 10(6):. PubMed ID: 29865280
[TBL] [Abstract][Full Text] [Related]
12. In vivo efficacy of decitabine as a natural killer cell-mediated immunotherapy against isocitrate dehydrogenase mutant gliomas.
Zhang X; Kim WJ; Rao AV; Jaman E; Deibert CP; Sandlesh P; Krueger K; Allen JC; Amankulor NM
Neurosurg Focus; 2022 Feb; 52(2):E3. PubMed ID: 35104792
[TBL] [Abstract][Full Text] [Related]
13. Overexpression of the Ubiquitin Specific Proteases USP43, USP41, USP27x and USP6 in Osteosarcoma Cell Lines: Inhibition of Osteosarcoma Tumor Growth and Lung Metastasis Development by the USP Antagonist PR619.
Lavaud M; Mullard M; Tesfaye R; Amiaud J; Legrand M; Danieau G; Brion R; Morice S; Regnier L; Dupuy M; Brounais-Le Royer B; Lamoureux F; Ory B; Rédini F; Verrecchia F
Cells; 2021 Aug; 10(9):. PubMed ID: 34571917
[TBL] [Abstract][Full Text] [Related]
14. BRCA1-associated RING domain-1 (BARD1) loss and GBP1 expression enhance sensitivity to DNA damage in Ewing sarcoma.
Maurer LM; Daley JD; Mukherjee E; Venier RE; Julian CM; Bailey NG; Jacobs MF; Kumar-Sinha C; Raphael H; Periyapatna N; Weiss K; Janeway KA; Mody R; Lucas PC; McAllister-Lucas LM; Bailey KM
Cancer Res Commun; 2022 Apr; 2(4):220-232. PubMed ID: 36187937
[TBL] [Abstract][Full Text] [Related]
15. Myelolytic Treatments Enhance Oncolytic Herpes Virotherapy in Models of Ewing Sarcoma by Modulating the Immune Microenvironment.
Denton NL; Chen CY; Hutzen B; Currier MA; Scott T; Nartker B; Leddon JL; Wang PY; Srinivas R; Cassady KA; Goins WF; Cripe TP
Mol Ther Oncolytics; 2018 Dec; 11():62-74. PubMed ID: 30505937
[TBL] [Abstract][Full Text] [Related]
16. Synthetic siRNA targeting the breakpoint of EWS/Fli-1 inhibits growth of Ewing sarcoma xenografts in a mouse model.
Takigami I; Ohno T; Kitade Y; Hara A; Nagano A; Kawai G; Saitou M; Matsuhashi A; Yamada K; Shimizu K
Int J Cancer; 2011 Jan; 128(1):216-26. PubMed ID: 20648560
[TBL] [Abstract][Full Text] [Related]
17. Anti-EGFR antibody cetuximab enhances the cytolytic activity of natural killer cells toward osteosarcoma.
Pahl JH; Ruslan SE; Buddingh EP; Santos SJ; Szuhai K; Serra M; Gelderblom H; Hogendoorn PC; Egeler RM; Schilham MW; Lankester AC
Clin Cancer Res; 2012 Jan; 18(2):432-41. PubMed ID: 22090361
[TBL] [Abstract][Full Text] [Related]
18. Boosting Natural Killer Cell-Mediated Targeting of Sarcoma Through DNAM-1 and NKG2D.
Sayitoglu EC; Georgoudaki AM; Chrobok M; Ozkazanc D; Josey BJ; Arif M; Kusser K; Hartman M; Chinn TM; Potens R; Pamukcu C; Krueger R; Zhang C; Mardinoglu A; Alici E; Temple HT; Sutlu T; Duru AD
Front Immunol; 2020; 11():40. PubMed ID: 32082316
[TBL] [Abstract][Full Text] [Related]
19. CDK9 Blockade Exploits Context-dependent Transcriptional Changes to Improve Activity and Limit Toxicity of Mithramycin for Ewing Sarcoma.
Flores G; Everett JH; Boguslawski EA; Oswald BM; Madaj ZB; Beddows I; Dikalov S; Adams M; Klumpp-Thomas CA; Kitchen-Goosen SM; Martin SE; Caplen NJ; Helman LJ; Grohar PJ
Mol Cancer Ther; 2020 May; 19(5):1183-1196. PubMed ID: 32127464
[TBL] [Abstract][Full Text] [Related]
20. Combinatorial immunotherapy of N-803 (IL-15 superagonist) and dinutuximab with ex vivo expanded natural killer cells significantly enhances in vitro cytotoxicity against GD2
Chu Y; Nayyar G; Jiang S; Rosenblum JM; Soon-Shiong P; Safrit JT; Lee DA; Cairo MS
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34244307
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
